U.S. stocks coasted to the close of another winning week with a quiet, mixed finish.

U.S. regulators have added another option for fall COVID-19 vaccination, updated shots made by Novavax.

Asian stock markets are mixed after signs of enduring upward pressure on American prices added to expectations of higher interest rates for longer.

Asian stock markets are mixed after signs of enduring upward pressure on American prices added to expectations of higher interest rates for longer.

The Centers for Disease Control and Prevention grants approves new type of COVID-19 vaccine

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax.

Health officials say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax.

The U.S. is getting another COVID-19 vaccine choice.

A COVID-19 vaccine that could soon win federal authorization may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have refused the other coronavirus vaccines for religious reasons.

A more traditional kind of COVID-19 vaccine is a step closer to becoming the fourth option for U.S. adults.

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine.

Japan’s health ministry has approved Novavax’s COVID-19 vaccine, and people could start getting the shots by late May.

The pharmaceutical developer Novavax says it has asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent.

The company behind a COVID-19 vaccine touted as a key tool for the developing world will miss a target for giving doses to the U.N.-backed effort to deliver shots to poorer countries.

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12.

The European Union’s executive commission has authorized a fifth COVID-19 vaccine for use in the 27-nation bloc Monday.

Biotechnology company Novavax says that Indonesia has given the world’s first emergency use authorization for its COVID-19 vaccine, which uses a different technology than current shots.

Britain says it it will offer new vaccinations to thousands of people who volunteered for trials of the Novavax coronavirus vaccine, which has not yet been approved for use in any country.

Vaccine maker Novavax is asking regulators in India, Indonesia and the Philippines to allow emergency use of its COVID-19 shot.

Vaccine maker Novavax says its shot is highly effective against COVID-19 and also protects against variants.

Aaralyn and Aryanna Politte are only 14 years old and part of the trial for Novavax.

On Thursday, Johnson and Johnson requested emergency authorization from the FD and now the Novavax vaccine is in the works. “I think it’s a promising candidate,” Dr. Jennifer Whitaker at the Baylor College of Medicine said. AdThe Novavax vaccine would require two shots 21 days apart. The Baylor College of Medicine started the Novavax clinical trial in January and has about 130 people enrolled. If you would like to take part in the Novavax clinical trial, click here for more information.

FILE - In this Tuesday, May 26, 2020 photo released by Nucleus Network/ABC, clinical trial participants are monitored during Novavax COVID-19 vaccine testing in Melbourne, Australia. The numbers are very small, but Novavax said they suggest the vaccine is nearly 96% effective against the older coronavirus and nearly 86% effective against the new variant. Results from a smaller Novavax study in that country suggests the vaccine does work but not nearly as well as it does against the variant from Britain. Tests suggested that nearly a third of study participants had been previously infected, yet rates of new infections in the placebo group were similar. Called a recombinant protein vaccine, the Maryland company uses genetic engineering to grow harmless copies of the coronavirus spike protein in insect cells.

LONDON – U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said. Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday. The trial is being conducted in partnership with the U.K. government’s Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine. The U.K. has already agreed to buy 60 million doses of the Novavax vaccine to ensure it can be distributed as quickly as possible if it is approved by regulators. The government said Friday that participants in the Novavax trial will be drawn from the 250,000 people who have volunteered to take part in COVID-19 vaccine testing through the National Health Service’s Vaccine Registry.

Despite the rally, the S&P 500 still posted its fourth straight weekly loss, extending Wall Street's September swoon. The S&P 500 rose 1.6% after flip-flopping between small gains and losses a few times in the early going. The S&P 500 came within striking distance of a 10% drop from its all-time high earlier this week, what Wall Street calls a correction. The S&P 500 rose 51.87 points to 3,298.46. Norwegian Cruise Line notched the biggest gain in the S&P 500, vaulting 13.7%.

The directive comes amid concerns about an uptick in coronavirus cases in certain Brooklyn and Queens neighborhoods with large Orthodox Jewish populations. New York City’s current overall infection rate remains low, but official figures indicate the affected neighborhoods accounted for 20% of the city’s coronavirus cases in recent weeks. ___BOSTON — An outbreak of coronavirus infections at a major Boston hospital has grown to 19 confirmed cases. ___DES MOINES, Iowa — Iowa has reported a jump of 1,086 new coronavirus cases, the second consecutive day of new cases exceeding 1,000. There are currently nearly 985,000 worldwide coronavirus deaths.

WASHINGTON The White House says President Donald Trump will visit North Carolina on Monday to tour a business that is participating in work on a COVID-19 vaccine. The White House said Trump is expected to speak about the collaboration between the administration and the private sector to rapidly develop a vaccine and ensure rapid distribution once ready. North Carolina is a key battleground state in the coming election, and Trumps visit marks his 10th trip to the state during his presidency. The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies Innovation Center in Morrisville, a suburb of Raleigh. The White House said the company is manufacturing key components of a COVID-19 vaccine candidate being developed by Novavax, an American vaccine development company based in Maryland.